RTA

RTA is a multi-receptor peptide agonist targeting GLP-1, GIP, and glucagon receptors, developed for the treatment of obesity and type 2 diabetes. By simultaneously modulating these three pathways, RTA provides a comprehensive metabolic approach, promoting weight loss, glycemic control, improved lipid metabolism, and enhanced energy expenditure. Its once-weekly subcutaneous administration improves patient adherence while maintaining therapeutic efficacy.

Weight Loss: Up to 24% body weight reduction in clinical trials; targets visceral fat
Glycemic Control: HbA1c reduction up to 2.2%; improves glucose homeostasis and insulin sensitivity
Energy Expenditure: Promotes thermogenesis and fatty acid oxidation through glucagon receptor activity
Appetite Regulation: Enhanced satiety and reduced caloric intake via GLP-1 and GIP pathways
Cardiovascular Health: Reduces triglycerides, improves lipid profile, lowers systolic blood pressure
Fat Loss & Body Composition: Preferential visceral fat reduction; maintains lean mass
Metabolic Flexibility: Optimizes glucose and lipid metabolism for overall metabolic health
Sustained Efficacy: Once-weekly dosing supports long-term adherence and durable metabolic effects

Jastreboff, A.M., et al. (2025). Efficacy and safety of RTA, a GLP-1, GIP, and glucagon receptor agonist for weight management in adults with obesity. Obesity Medicine, 15, 100523. DOI.
Enebo, L.B., et al. (2023). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Obesity, 31(2), 296-308. DOI.
Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, phase 2 trial. The Lancet, 402(10401), 529-544. DOI.

$173.00

Per Unit

In stock